Pharmaceutical

Lilly strikes deal with QurAlis for preclinical ALS candidate

QRL-204 is designed to restore UNC13A function, a gene identified as a risk factor in neurodegenerative diseases including ALS and dementia.

Jun 4, 2024 - 04:00
Lilly strikes deal with QurAlis for preclinical ALS candidate
QRL-204 is designed to restore UNC13A function, a gene identified as a risk factor in neurodegenerative diseases including ALS and dementia.
Read the original article

Tags:

Previous Article

ASCO 2024: Tagrisso approaches standard of Care status for NSCLC

Next Article

GRIT and Quangang announce IL-2 T-cell therapy partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

To detect breast cancer sooner, an MIT professor designs an ultrasound bra

To detect breast cancer sooner, an MIT professor design...

Jul 28, 2023

Opinion: California should become the first state to offer a special minimum wage to health care workers

Opinion: California should become the first state to of...

Jul 8, 2023

TLM-003 by Therillume for Glioblastoma Multiforme (GBM)...

Nov 6, 2023